An interventional study of a microstream capnography nasal end-tidal carbon dioxide sampling tube in Hypoxemia, sponsored by Chinese PLA General Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Chinese PLA General Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Hypoxia with a site in China — 44 open to participants now, 45 under way, none of them phase 3. Hypoxia · China.
Among the 97 studies in Hypoxia with a site in China, this one is the 25th largest by planned enrollment of the 78 interventional ones that give a count, is one of 19 that started in 2026, is one of 63 with no phase, reaches primary completion later than 24 of the 44 other live ones, and was the 78th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →44 of the 97 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18+
General Hospital of Ningxia Medical University · Sites in China
Ages 18+
General Hospital of Ningxia Medical University · Sites in China
Ages 18+
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
Wenxian Li · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 1 · Phase 4 3
First in 2009; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 460 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 240 across the 78 interventional studies, 120 across the 19 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 97 have an industry lead sponsor. The 10 most frequent:
Chinese PLA General Hospital is the lead sponsor of 574 studies on the registry; 209 are open to participants now.
Chinese PLA General Hospital has 4 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
15 of the studies in Hypoxia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07748884Second Affiliated Hospital of Wenzhou Medical UniversityComparing Esketamine and Remazolam With Propofol for Breathing Safety in Pediatric Gastroscopy | 2026-12 |
| NCT07395596First Affiliated Hospital of Zhejiang UniversityRemimazolam for Bronchoscopy in High-Risk Patients | 2026-12 |
| NCT07307560Zhejiang UniversityHigh-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients | 2026-12-01 |
| NCT07051980Zhejiang UniversityFeasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study | 2026-12-02 |
| NCT06966934Nanjing First Hospital, Nanjing Medical UniversityNasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients | 2026-12-15 |
Add all 15 to your calendar (.ics) → With an account.
Among the 97 studies in Hypoxia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Using Capnography for Safer Sedation in Painless Gastrointestinal Endoscopy
Why is this study important? For procedures like painless gastroscopy and colonoscopy, patients receive sedation to ensure comfort. However, traditional monitoring (like checking heart rate and blood oxygen levels) can only detect breathing problems after they have already caused a drop in oxygen. This delay can be risky, especially for elderly patients whose breathing function is naturally weaker. This study looks at a better way to monitor patients.
What is the new method? This study focuses on a technology called real-time end-tidal carbon dioxide (ETCO₂) monitoring, also known as capnography. It is a simple, non-invasive device that continuously measures the carbon dioxide a patient breathes out. This provides an early warning system for doctors, alerting them to breathing issues (like a pause in breathing or an airway blockage) much sooner than traditional monitors can.
What did the study find?
Based on extensive research and clinical experience both in China and internationally (including the US and Europe), integrating ETCO₂ monitoring into painless digestive endoscopy procedures leads to significant improvements in patient safety:
Value for Patients, Families, and Providers:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patient was positioned in the left lateral decubitus position, with oxygen being administered via nasal cannula at a rate of 2 liters per minute(2L/min). End-tidal carbon dioxide (ETCO2) was collected using a microstream capnography nasal sampling tube. Both groups of patients wore nasal cannulas for end-tidal carbon dioxide monitoring. the control group (C group) had the capnograph monitor screen obscured and the machine sound muted.
The patient was positioned in the left lateral decubitus position, with oxygen being administered via nasal cannula at a rate of 2 liters per minute(2L/min). End-tidal carbon dioxide (ETCO2) was collected using a microstream capnography nasal sampling tube. Both groups of patients wore nasal cannulas for end-tidal carbon dioxide monitoring. The observation group (T group) viewed the capnograph monitor (Capnostream 20P Patient Monitor, Medtronic Inc., Minnesota, Minneapolis, USA), screen and heard the initiation sound of the machine.
Device: a microstream capnography nasal end-tidal carbon dioxide sampling tube
In addition to routine monitoring (ECG, NIBP, and SpO2), a microstream capnography nasal end-tidal carbon dioxide sampling tube is used for end-tidal carbon dioxide capnography monitoring.
incidence of hypoxemia
Incidence of SpO₂ \< 95%(%)
Time frame: During gastrointestinal endoscopy
Duration of hypoxemia
Duration of of SpO₂ \< 95%(seconds)
Time frame: During gastrointestinal endoscopy
Incidence of movement
Incidence of movement(%)
Time frame: during gastrointestinal endoscopy
Plan to share: Undecided
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 9 months is below that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
Completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Dec 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese PLA General Hospital →